Anaptysbio, Inc. · NASDAQ:ANAB
Anaptysbio — Jefferies Virtual Healthcare Conference 2021
33 slides from Anaptysbio's conference presentation, Jun 3, 2021
Slide 1: Corporate Overview
AnaptysBi oW Corporate Overview Jefferies Virtual Healthcare Conference June 3 2021 Nasdaq: ANAB
Slide 2: Safe Harbor Statement
Safe Harbor Statement Vv This presentation and any accompanying oral presentation contain “forward-looking” statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to: the timing of the release of data from our
Slide 3: AnaptysBio: Clinical-Stage Novel Antibody R&D Engine
AnaptysBio: Clinical-Stage Novel Antibody R&D Engine \4 Advancing First-In-Class Immunology Therapeutics to Patients 4 Wholly-Owned Multiple imsidolimab Phase 2 readouts anticipated over upcoming 18 months, Clinical Catalysts in addition to advancement of imsidolimab into GPP Phase 3 trials 7 immuno
Slide 4: Wholly-Owned Product Pipeline
Wholly-Owned Product Pipeline VY 7 Immuno-Dermatology Indications Under Phase 2/3 Development During 2021 Antibody Therapeutic Development Stage & Anticipated Milestones Program Indication Discovery Preclinical Phase 1 Phase 2 Phase 3 Generalized GALLOP: Phase 2 Data To Be Presented At Phase 3 Initi
Slide 5: Partnered Product Pipeline
Partnered Product Pipeline Vv Earning Royalties on JEMPERLI™ and Zejula™ Starting 2021 Hiei Development Stage & Anticipated Milestones Commercial Antibody Program ape 5 Felachce Discovery Preclinical Phase 1 Phase 2 Phase 3 Marketed Rights MMR Endorretrial USBLAandEU MAA Cancer Approved Apri 2021 JE
Slide 6: Anticipated Wholly-Owned Clinical Catalysts
Anticipated Wholly-Owned Clinical Catalysts Y Program Clinical Catalyst Timing GALLOP: GPP Phase 2 Trial GEMINI-1 & 2: GPP Phase 3 Trials EMERGE: EGFRi/MEKi Mediated Skin Imsidolimab Toxicity Phase 2 Trial (ANBO19, anti-IL-36R) INSPIRE: Ichthyosis Phase 2 Trial ACORN: Acne Phase 2 Trial HARP: Hidrad
Slide 7: Wholly-Owned Pipeline: Imsidolimab (ANB019, Anti-IL-36R)
AnaptysBi oW Wholly-Owned Pipeline: Imsidolimab (ANB019, Anti-IL-36R) Generalized Pustular Psoriasis EGFRi-Mediated Skin Toxicity Ichthyosis Hidradenitis Suppurativa Acne
Slide 8: IL-36 Dysfunction Mediates Severe Inflammatory Disease
IL-36 Dysfunction Mediates Severe Inflammatory Disease Vv Genetic Association with Generalized Pustular Psoriasis Normal Individuals Disease Patients Treated Patients IL-36 cytokine signaling balanced by Uncontrolled signaling due to dystuncslonal Anti-IL-36R antibody has the potential to function I
Slide 9: Generalized Pustular Psoriasis (GPP)
Generalized Pustular Psoriasis (GPP) VY Orphan Disease Associated with IL-36 Receptor Antagonist Mutations * GPP is a systemic, life-threatening inflammatory disease characterized by widespread pustules - Patients have a high fever and elevated levels of serum CRP and inflammatory cytokines (e.g. IL
Slide 10: GALLOP: Imsidolimab Moderate-to-Severe GPP Phase 2 Trial
GALLOP: Imsidolimab Moderate-to-Severe GPP Phase 2 Trial Vv Trial Design Treatment Period Monitoring Period -2 2g 2g zs Se S$ °8 ae ag Imsidolimab 750mg IV Loading Dose + 100mg SC q4w Maintenance Dose Screening Day 29 Interim Analysis Patient + Moderate-to-severe adult generalized pustular psoriasis
Slide 11: GALLOP: Imsidolimab Interim Data
GALLOP: ih ib 2 Interim ane Ba / With Imsid Monotherap 024 2027 Rapid Onset a ticipate Baseline D8V8Relativeto Day 29 Relat Endpoi * Rapid and promising efficacy poseane toecelizg i A . 7 hi = 6 of 8 patients achieved primary endpoint of RSG. F ; ; improvement in the clinical global impression scale
Slide 12: GEMINI-1 & 2: Imsidolimab GPP Phase 3 Trials
GEMINI-1 & 2: Imsidolimab GPP Phase 3 Trials \ 45 patients randomized through Week 4 primary endpoint followed by 24-week long-term extension A Anticipate GEMINI-1 initiation in Q3 2021 © GEMINI-1: 4-Week = ° GEMINI-2: 24-Week & 3 Primary Endpoint 3 3 Long-Term Extension 3 = Ss Ss = ___| Imsidolimab
Slide 13: New Indication: EGFRi/MEKi-Mediated Skin Toxicity
New Indication: EGFRi/MEKi-M iated Skin Toxicity W ¢ Papulopustular rash is the most frequent clinically significant dermatological toxicity associated with EGFR/MEK inhibitor solid tumor treatment ¢ Majority of patients experience dose-limiting skin toxicity and/or discontinuation of EGFR/MEK inhib
Slide 14: EMERGE: Imsidolimab EGFRi/MEKi-Mediated Skin Tox Phase 2 Trial
EMERGE: Imsidolimab EGFRi/MEKi-Mediated Skin Tox Phase 2 Trial Y Interim Top-Line Data Anticipated End 2021 Treatment Period Monitoring Period Week 1 Week 16 Week 24 Imsidolimab 400mg SC Loading Dose + 200mg SC q4w Maintenance Dose Placebo Week 8 Interim Analysis Patient * Adult patients undergoing
Slide 15: New Indication: Ichthyosis
New Indication: Ichthyosis VY Orphan Disease Associated With Excess IL-36 Signaling * Ichthyosis is a rare, orphan dermatological indication with high medical unmet need * Patients suffer from dry, scaly skin, often leading to itch and painful cracking * Translational studies have demonstrated high
Slide 16: INSPIRE: Imsidolimab Ichthyosis Phase 2 Trial
INSPIRE: Imsidolimab Ichthyosis Phase 2 Trial YY Interim Top-Line Data Anticipated in 2022 = Treatment Period © Extension Period Follow-Up Period 3 2 a 8 Imsidolimab 400mg SC Loading Dose + 3 i 200mg SC q4w Maintenance Dose |__| All Patients Receive 200mg SC qaw Maintenance Dose Placebo Patient * Pa
Slide 17: New Indication: Moderate-to-Severe Acne Vulgaris
New Indication: Moderate-to-Severe Acne Vulgaris VY Large Market Opportunity Associated with IL-36 Signaling * Acne vulgaris is the most common skin disorder in the United States, with approximately 7 million patients diagnosed with moderate-to- severe disease * Believed to be driven by immune respo
Slide 18: ACORN: Imsidolimab Acne Vulgaris Phase 2 Trial
ACORN: Imsidolimab Acne Vulgaris Phase 2 Trial VY Top-Line Data Anticipated in H1 2022 Follow-Up Period Treatment Period Week 12 Week 20 Imsidolimab 400 mg SC + 200 mg SC q4w Imsidolimab 200 mg SC + 100 mg SC q4w Placebo Patient Population Patients (12-45 years old) with moderate to severe acne vulg
Slide 19: New Indication: Hidradenitis Suppurativa
New Indication: Hidradenitis Suppurativa Y IL-36 Cytokine Over-Expression Observed in Patient Skin Biopsies * Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease - Painful nodules present in intertriginous areas that progress to abscesses, sinus tracks and scarring * Current treatme
Slide 20: HARP: Imsidolimab Hidradenitis Suppurativa Phase 2 Trial
HARP: Imsidolimab Hidradenitis Suppurativa Phase 2 Trial VY Top-Line Data Anticipated in H2 2022 ° © x g s , x Extension ‘% Follow-Up *¥ g Treatment Period 8 Period 8 Period 8 Imsidolimab 400 mg SC + 200 mg SC q4w Imsidolimab 200 mg SC + 100 mg SC q4w Placebo patients re- randomized 1:1 to above Pl
Slide 21: Wholly-Owned Pipeline: Anti-PD-1 Agonist (ANB030), Anti-BTLA Modulator (ANB032)
AnaptysBi oW Wholly-Owned Pipeline: Anti-PD-1 Agonist (ANB030) Anti-BTLA Modulator (ANB032) Inflammatory Diseases
Slide 22: Anti-Inflammatory Checkpoint Receptor Antibodies
Anti-Inflammatory Checkpoint Receptor Antibodies Novel Therapeutic Class Validated By Human Genetics Anti-inflammatory checkpoint receptor antibodies have unique binding properties that are challenging to generate using traditional antibody technologies AnaptysBio’s technology platform has successfu
Slide 23: ANB030: PD-1 Agonist Antibody
ANBO030: PD-1 Agonist Antibody VY Novel Anti-Inflammatory Mechanism Applicable to T-Cell Driven Inflammatory Conditions Z ar & , Activated T Cell Antigen Presenting Cell « PD-1 is a key inhibitory immune checkpoint receptor responsible for down-regulating T- cell mediated immune responses Healthy °
Slide 24: ANB032: BTLA Modulator Antibody
ANB032: BTLA Modulator Antibody Emerging Lymphoid and Myeloid Immune Control Mechanism Broadly Applicable to Inflammatory Disease BTLA is an inhibitory checkpoint receptor responsible for regulating activation of lymphoid (T and B) cells and myeloid (dendritic) cells Genetic defects in the BTLA path
Slide 25: Partnered Pipeline: GSK Immuno-Oncology Collaboration
AnaptysBi oW Partnered Pipeline: GSK Immuno-Oncology Collaboration JEMPERLI™ (dostarlimab, anti-PD-1 Antagonist) Cobolimab (GSK4069889, anti-TIM-3 Antagonist) TSR-033 (GSK4074386, anti-LAG-3 Antagonist)
Slide 26: $40MM regulatory milestones from JEMPERLI in H1 2021
$40MM regulatory milestones from JEMPERLI™ (dostarlimab) in H1 2021 GSK Immuno-Oncology Collaboration VY Earning royalties from sales of JEMPERLI and Zejula™ GARNET (n=125) dMMR Endometrial US and EU Approval Granted April 2021 en RUBY Key Financial Terms * $1.1B in aggregate milestone BLA Accepted
Slide 27: Proprietary Technology Platform
AnaptysBi oW Proprietary Technology Platform
Slide 28: Somatic Hypermutation (SHM) Platform
Somatic Hypermutation (SHM) Platform YY Proprietary Platform Incorporates in vitro SHM and Iterative Antibody Evolution In Vitro SHM Iterative Antibody Evolution 4 Y y Starting AlD-Induced \ f 1. Library SHM ye Selecti \ Q x ‘election aw 4 we Wy iy © 9 cs: 69 — ty — Ye — YY Optimized AID-Induced Ant
Slide 29: Somatic Hypermutation (SHM) Platform: Advantages Over Competing Technologies
Somatic Hypermutation (SHM) Platform \f Advantages Over Competing Antibody Technologies 7 Unprecedented antibody diversity through SHM — In-situ antibody diversity generation outside of the constraints of an in vivo environment High potency & functional activity — Only small doses may be required to
Slide 30: Summary
AnaptysBi oW Summary
Slide 31: Anticipated Wholly-Owned Clinical Catalysts
Anticipated Wholly-Owned Clinical Catalysts YY Program Clinical Catalyst Timing GALLOP: GPP Phase 2 Trial GEMINI-1 & 2: GPP Phase 3 Trials EMERGE: EGFRi/MEKi Mediated Skin Imsidolimab Toxicity Phase 2 Trial (ANBO19, anti-IL-36R) INSPIRE: Ichthyosis Phase 2 Trial ACORN: Acne Phase 2 Trial HARP: Hidra
Slide 32: AnaptysBio: Clinical-Stage Novel Antibody R&D Engine
AnaptysBio: Clinical-Stage Novel Antibody R&D Engine Advancing First-In-Class Immunology Therapeutics to Patients < Wholly-Owned Multiple imsidolimab Phase 2 readouts anticipated over upcoming 18 months, Clinical Catalysts in addition to advancement of imsidolimab into GPP Phase 3 trials 7 immuno-de
Slide 33: AnaptysBi oW
AnaptysBi oW
Anaptysbio — Jefferies Virtual Healthcare Conference 2021 on 6ix